CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor therapy with Amanita phalloides (Death Cap): stabilization of mammary duct cancer

  • Received : 2011.05.30
  • Accepted : 2011.11.30
  • Published : 2011.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Molecular events that cause tumor formation enhance a number of HOX genes, called switch genes, coding for RNApolymeraseII transcription factors. Thus, in tumor cells, RNApolymeraseII is more active than in other somatic cells. Amanita phalloides contains amanitin which inhibits RNApolymeraseII. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. To widen the treatment spectrum, dilutions of Amanita phalloides, containing amanitin, are applied to a patient with mammary duct cancer. For monitoring tumormarkers, different doses of amanitin are applied. The former duplication time of tumor growth represented three months; however within a period of 18 months the patient can be stabilized without further growth of the tumor. There are also no severe symptoms, no liver damage and no continuous erythrocyte deprivation. This new principle of tumor therapy shows high potential to provide a medical treatment.

Keywords

References

  1. Barrett JC, Oshimura M, Koi M. Role of oncogenes and tumor suppressor genes in a multistep model of carcinogenesis. Symp Fundam Cancer Res. 1986;39:45-56.
  2. Bishop JM. Viral oncogenes. Cell. 1985;42(1):23-38. https://doi.org/10.1016/S0092-8674(85)80098-2
  3. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71(4):701-708. https://doi.org/10.1016/0092-8674(92)90603-A
  4. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, Rao MK. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogen in human cancers. Oncogene. 2010;29:4971-4979. https://doi.org/10.1038/onc.2010.233
  5. Orlovsky K, Kalinkovich A, Rozovskaia T, Shezen E, Itkin T, Alder H, Ozer HG, Carramusa L, Avigdor A, Volinia S, Buchberg A, Mazo A, Kollet O, Largman C, Croce CM, Nakamura T, Lapidot T, Canaani E. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A. 2011;108(19):7956-7961. https://doi.org/10.1073/pnas.1103154108
  6. Riede I. Proliferative genes induce somatic pairing defects in Drosophila melanogaster and allow replication. Cancer Genet Cytogenet. 1997;97(2):143-154. https://doi.org/10.1016/S0165-4608(96)00396-2
  7. Riede I. Switch Genes in Tumor Formation, Drosophila Information Service. 2004;87:54-59.
  8. Riede, I. Tumor Therapy with Amanita phalloides (Death Cap): Stabilization of B-Cell Chronic Lymphatic Leukemia. J Altern Complement Med. 2010;16(10):1129-1132. https://doi.org/10.1089/acm.2010.0035
  9. Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene 2001;20(7):874-878. https://doi.org/10.1038/sj.onc.1204174
  10. Svingen T, Tonissen KF. Altered HOX gene expression in human skin and breast cancer cells. Cancer Biol Ther. 2003;2:518-523. https://doi.org/10.4161/cbt.2.5.441
  11. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010;70(21):8487-8497. https://doi.org/10.1158/0008-5472.CAN-10-1013